Search

Describes several case reports on the side effects of various drugs. Occurrence of uveities following ophthalmic administration of bimatropost in an elderly patient; Details of a case of a possible interaction between itraconazole and inhaled budesonide resulted in Cushing's syndrome in a 70-year old woman; Occurrence of aseptic meningitis in a 65-year old woman during treatment with celecoxib for osetoarthritis.

The article presents a case study of a 37-year-old woman who developed DRESS syndrome and reactivation of Familial Mediterranean fever (FMF) during treatment with sulfasalazine for spondyloarthritis.

The article presents a case study of a 30-year-old man who developed DRESS syndrome during treatment with sulfasalazine for ankylosing spondylitis.

The article describes the case of a 66-year-old woman who developed mild proximal myopathy during long-term treatment with hydroxychloroquine for rheumatoid arthritis, which progressed to acute decompensation during concomitant treatment with colchicine. Upon presentation, the patient reported experiencing progressive proximal upper and lower extremity muscle and mild weakness. Her creatine kinase level normalised and her strength returned after colchicine and hydroxychloroquine were discontinued.

The article describes the case of a 50-year-old patient who developed neutropenic enterocolitis during treatment with sulfasalazine for arthritis. A brief overview is given on the medical history of the patient. Clinical manifestations of the adverse effects of the drug include subjective fever, acute onset abdominal pain, and tenderness.

The article presents case reports of two pregnant women who developed oligohydramnios during treatment with diclofenac. It informs that the fetus of one patient had an insufficiently filled urinary bladder. The second patient had Kartagener's syndrome and rheumatoid arthritis, and had been receiving methotrexate, which was replaced by diclofenac when pregnancy was planned.

The article describes the case of a 29-year-old woman who developed drug hypersensitivity with eosinophilia and systemic symptoms syndrome while receiving celecoxib for suspected arthritis and antituberculars for tuberculosis. After discovery of drug hypersensitivity, celecoxib and all antituberculars were discontinued. She started receiving corticosteroids, antibacterials and ursodeoxycholic acid.

Discusses research being done on the adverse reaction of the drug naproxen. Reference to a study by Heikkilä H. et al, published in the July 2004 issue of "British Journal of Dermatology"; Condition of a man who developed a generalized bullous fixed drug eruption after receiving naproxen; Actions taken to address his condition.

Presents a case study of a patient who has developed aphthous stomatitis associated with oral piroxicam therapy. Side effects of the drug on the patient; Medical test underwent by the patient.

The article presents case studies of a 29-year-old woman who received IV tocilizumab 8-mg/kg per month for ankylosing spondylitis and developed mouth ulcers seven days after her second infusion, and a 63-year woman who developed lesions during treatment with tocilizumab for rheumatoid arthritis.

The article describes the case of a 64-year-old woman who experienced oral pigmentation while undergoing treatment with chloroquine diphosphate for rheumatoid arthritis.

The article describes the case of a 58-year-old woman who developed Whipple's disease while under a treatment regimen with etanercept for arthritis. The patient started receiving etanercept in 2005 and complained a history of a dull ache in her upper abdomen, nausea, meteoism and postprandial abdominal pain. Laboratory findings on the patient were suggestive of Whipple's disease with an infiltration of plump histiocytes. She was given ceftriaxone and cotrimoxazole which improved her condition.

The article describes the case of a woman who developed hepatitis after commencing therapy with sulfasalazine for rheumatoid arthritis (RA). The patient experienced a generalized pruritic body rash, facial swelling, vomiting and decreased appetite. The patient's liver function also continued to deteriorate. Her liver function tests improved after her prednisolone dosage was doubled and after she received vitamin K.

The article describes the case of a female patient who developed pruritic rashes after receiving celecoxib for osteoarthritis. Celecoxib was discontinued because multifocal fixed drug eruption was suspected. She was given ebastine, tetracosactide, and desoximetasone cream. A positive patch testing with celecoxib resulted two months following the resolution of her rash.

The article describes the case of a 43-year-old woman who developed sero-negative arthritis after receiving sulfasalazine. She was found to have hepatic cytolysis and atypical lymphocytes. Histological analysis revealed a dermal lymphoplasmocytic infiltrate, mainly surrounding vessels, in the patient. Though the drug was discontinued, her condition only resolved after treatment with prednisone.

The article describes the case of a 49-year-old man with arthritis who presented with a three-month history of painful erosive ulcers on both sides of his tongue in relation to oral alendronic acid administration. The patient claimed that he dissolves the alendronic acid in his mouth because he had difficulty swallowing it. A biopsy on the patient showed acutely inflamed non-specific ulcers and candidiasis. He was given antifungal therapy and a benzydamine mouth wash with marginal response.

The article describes the case of a 52-year-old woman who developed alopecia areata wile under a weekly adalimumab treatment regimen for psoriatic arthritis. Two weeks after receiving her second weekly injection of adalimumab, the patient developed a white, pruritic rash on her extremities. She also experienced hair loss on her occipital region.

The article describes a case of naproxen-induced anemia and hypoalbuminemia in a 16-month-old child. The boy received naproxen for the treatment of oligoarticular juvenile rheumatoid arthritis. It relates the symptoms presented by the patient consistent with hypoalbuminaemia and iron deficiency anemia. It discusses the treatment administered to the patient and its outcomes.

The article describes two cases of women who developed ototoxicity while receiving treatment with hydroxychloroquine and chloroquine for rheumatoid arthritis (RA). One of the patients, a 42-year-old woman, experienced sudden loss of hearing in her right ear, along with ringing and fullness in her ear. Her tinnitus improved after hydroxychloroquine. Particular focus is given to the dosing regimen of another patient, a 55-year-old woman. The results of her laboratory tests are also provided.

The article presents information on a study which investigated the adverse effect of the drug celecoxib. According to results from the Celecoxib Cross Trial Safety Analysis, different celecoxib doses and regimens are associated with differences in the risk of cardiovascular events. The researchers note that the data support the recent American Heart Association scientific position statement suggesting that physicians should prescribe the lowest doses of celecoxib possible, especially in higher-risk patients.

The article describes a case of diaphragm disease associated with rofecoxib treatment in a 52-year-old woman with rheumatoid arthritis. Rofecoxib therapy was initiated in the patient to treat her recurrent small-bowel obstruction. Small bowel resection was performed on the patient after diagnosing diaphragm disease.

The article reports on the effectiveness of ocrelizumab and methotrexate in the treatment of rheumatoid arthritis (RA) based on a trial. It involves 237 patients who received the combination therapy, ocrelizumab alone and placebo for 72 weeks. The rates of serious adverse effects were found similar between the combination therapy, ocrelizumab and placebo groups. Reduction in C-reactive protein level and low immunogenicity were noted in the combination therapy group.

The article reports on the increased risk of adverse cardiovascular events associated with rofecoxib based on a Vioxx in Colorectal Cancer Therapy: Definition of Optimal Regime (VICTOR) study by D. J. Kerr et al published in the July 2007 issue of the "New England Journal of Medicine." The study initially hypothesized that rofecoxib will decrease tumor recurrence rates in patients who underwent colorectal cancer surgery. The subjects of the study were randomized to receive rofecoxib or placebo.

The article reports that EMEA has recommended restrictions on piroxicam-containing products due to a risk of GI adverse effects and serious skin reactions. A press release by the agency's Committee for Medicinal Products for Human Use (CHMP) has determined that piroxicam should no longer be used for short-term painful and inflammatory conditions.

The article compares the cardiovascular risk posed by celecoxib and rofexocib according to a study from South Korea. The study found that the cardiovascular risks posed by celecoxib and rofecoxib are similar. The impact of the drugs on cardiovascular events such as myocardial infarction and angina pectoris are evaluated. The dosage used in the study are mentioned.

The article discusses research being done on rofecoxib. It references a study by V. J. Colucci et al published in the May-June 2006 issue of the "Journal of Pharmacy Technology." A 62-year old man developed complications while taking rofecoxib for the treatment of back injury. He experienced syncope and stroke with worsened back pain.

The article discusses research being done on the adverse drug reaction to Arcoxia (etoricoxib). According to the findings of a preliminary drug analyses, Arcoxia appears to be associated with a similar rate of thrombotic cardiovascular events, in patients with arthristis, but a higher rate of discontinuations due to hypertension- and oedema-related adverse events compared with diclofenac.

The article discusses research being done on the adverse drug reaction to cyclooxygenase 2 inhibitors. It references a study by F. Andersohn et al, which appeared in the July 2006 issue of the journal "Stroke." According to the results of a nested case-control study, the use of rofecoxib and etoricoxib, but not of celecoxib, appears to be associated with an increased risk of ischaemic stroke compared with no use.

The article discusses research being done on the adverse effects of anakinra administration on an aged man for the treatment of his rheumatoid arthritis. It references a study by D. Wendling and colleagues, published in the May 2006 issue of "Joint Bone Spine." Information on the medical history of the patient is presented.

The article discusses research being done on link between the long-term use of celecoxib or rofecoxib and cardiovascular events. It references a study by S. P. Motsko and colleagues, published in the 2006 issue of "Drug Safety." The methodology of the study is described. A comparison between long-term use of celecoxib, rofecoxib and ibuprofen is presented.

The article reports on a case of an aged man who developed acute interstitial nephritis while receiving glucosamine for the treatment of osteoarthritis. The medical history of the patient is presented. The findings of an ultrasound and renal biopsy on the patient are highlighted. The treatment administered to him is also mentioned.

Discusses research on the off-drug extension of the Adenomatous Polyp Prevention on Vioxx. Reference to a study published in the May 11, 2006 issue of "Media Release"; Findings from follow-up data from day 15 postdiscontinuation of study therapy; Adverse effects of the drug.

Presents the results of the preliminary analyses of the off-drug extension of the Adenomatous Polyp Prevention on Vioxx (APPROVe). Impact of rofecoxib, APPROVe on the risk of cardiovascular adverse event in patients who had previously received Vioxx; Myocardial infarction and stroke among rofecoxib recipients.

Discusses research being done on the adverse-drug reaction to celecoxib. Reference to study being done by Z. Houmani et al., which appeared in the December 2005 issue of the journal "Gastroenterologie Clinique et Biologique"; Overview of the medical condition of a patient who developed acute colitis after starting celecoxib therapy.

Discusses research being done on the adverse-drug reaction to celecoxib. Reference to study being done by P. Chamouard et al., which appeared in the December 2005 issue of the journal "Gastroenterologie Clinique et Biologique"; Overview of the medical condition of a patient who developed severe and prolonged cholestasis after short-term treatment with celecoxib.

The article discusses research being done on the high rate of Stevens-Johnson syndrome and toxic epidermal necrolysis (TEN) with the use of valdecoxib in the U.S. It references a study by L. La Grenade et al in the 2005 issue of "Drug Safety." The incidence of SJS and TEN which resulted from the use of celecoxib, rofecoxib and meloxicam were compared in the study. The of side effects for valdecoxib were higher than that of the background incidence rate.

Discusses a case report of a 40-year-old woman who developed parkinsonism during treatment with adalimumab for rheumatoid arthritis. Reference to a study by R. Tintner et al, published in a 2005 issue of the "Movement Disorders"; Concomitant medication taken by the patient; Results after 2 months of discontinued use of adalimumab.

Discusses a case report of an aged man who developed dermatomycoses during treatment with adalimumab for rheumatoid arthritis. Reference to a study by L. Kos, et al, published in the March 2005 issue of the "Journal of the American Academy of Dermatology"; Dosage of adalimumab received by the man every other week.

Discusses research being done on the incidence of thrombotic cardiovascular events associated with celecoxib and rofecoxib. Reference to a study by J. Ashton et al, published in a 2005 issue of the "Drug Safety"; Number of patients receiving celecoxib who experienced thrombotic cardiovascular events.

Presents a case report on acute generalized exanthematous pustulosis caused by celecoxib. Description of exanthematous pustulosis; Information on the treatment of the disease; Association between drug intake and onset of skin eruption.

Discusses research being done on a man who developed fragility and blistering of the skin on the dorsum of his hands caused by taking naproxen for treating osteoporosis. Reference to a study by I. Coulson et al published in the March 19, 2005 online issue of "BMJ"; Effect of naproxen discontinuation on the patient.

Discusses research being done on two women who developed fixed drug eruptions during treatment with piroxicam. Reference to a study by E. C. Galindo, J. M. G. Silva, M. V. Hernando, et al., published in the September 2004 issue of the "Journal of the European Academy of Dermatology and Venereology"; Adverse drug reactions associated with the treatment; Results of the patch test conducted on the two patients.

Introduces the article "Obliterating Bronchiolytis Induced by D-penicillamine in a Female Patient With Systemic Sclerosis," by A. T. Alekperov et al. in a 2004 issue of "Terapevticheskii Arkhiv."

Discusses research being done on the safety profile of celecoxib as used in general practice in England. Reference to a study by Layton and colleagues published in the September 2004 issue of the "European Journal of Clinical Pharmacology"; Reasons for stopping celecoxib treatment; Adverse drug reactions to celecoxib.

Presents information on a study by B. Milpied and colleagues on sever cutaneous drug reactions to celecoxib, published in the November 2003 issue of the "Annales de Dermatologie et de Venereologie" journal.